Companies unleash broadside again after NICE’s final Enhertu guidance

29 July 2024

The National Institute for Health and Care Excellence (NICE) has published final guidance which does not recommend Enhertu (trastuzumab deruxtecan) for treating advanced HER2-low breast cancer in adults in England.

NICE found that Enhertu—the first and only HER-2 therapy licensed in the UK to demonstrate efficacy in a HER2-low breast cancer population—is not a cost-effective treatment.

Enhertu is already recommended for use in the NHS for other types of breast cancer in England via the Cancer Drugs Fund and, in HER2-low breast cancer, it has been reimbursed in Scotland since December 2023 as well as in 13 other countries in Europe, including Germany and Italy, as well as Canada.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK